Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study

Guin, Aharna; Chatterjee, Maitrayee; Chakraborty, Sumit; Sinhamahapatra, Pradyot; Ghosh, Alakendu

doi:10.1016/j.semarthrit.2012.12.027

Cited by 46 publications

(31 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Disease-modifying antirheumatic drugs (DMARDs) were shown to reduce progression of atherosclerosis in patients with RA in several studies 87–89…”

Section: Cardiovascular Care In Rheumatologymentioning

confidence: 99%

“…Interestingly, a group of patients with RA, subclinical atherosclerosis, and endothelial dysfunction was reassessed prospectively after DMARD therapy: after 1 year, both the carotid intima–media thickness and endothelial-dependent flow-mediated vasodilatation were improved 89. Anti-TNF therapies can also reduce atherosclerosis-promoting systemic inflammation.…”

Section: Cardiovascular Care In Rheumatologymentioning

confidence: 99%

See 1 more Smart Citation

Cardiorheumatology: cardiac involvement in systemic rheumatic disease

et al. 2014

View full text Add to dashboard Cite

Autoimmune rheumatic diseases can affect the cardiac vasculature, valves, myocardium, pericardium, and conduction system, leading to a plethora of cardiovascular manifestations that can remain clinically silent or lead to substantial cardiovascular morbidity and mortality. Although the high risk of cardiovascular pathology in patients with autoimmune inflammatory rheumatological diseases is not owing to atherosclerosis alone, this particular condition contributes substantially to cardiovascular morbidity and mortality—the degree of coronary atherosclerosis observed in patients with rheumatic diseases can be as accelerated, diffuse, and extensive as in patients with diabetes mellitus. The high risk of atherosclerosis is not solely attributable to traditional cardiovascular risk factors: dysfunctional immune responses, a hallmark of patients with rheumatic disorders, are thought to cause chronic tissue-destructive inflammation. Prompt recognition of cardiovascular abnormalities is needed for timely and appropriate management, and aggressive control of traditional risk factors remains imperative in patients with rheumatic diseases. Moreover, therapies directed towards inflammatory process are crucial to reduce cardiovascular disease morbidity and mortality. In this Review, we examine the multiple cardiovascular manifestations in patients with rheumatological disorders, their underlying pathophysiology, and available management strategies, with particular emphasis on the vascular aspects of the emerging field of ‘cardiorheumatology’.

show abstract

“…Disease-modifying antirheumatic drugs (DMARDs) were shown to reduce progression of atherosclerosis in patients with RA in several studies 87–89…”

Section: Cardiovascular Care In Rheumatologymentioning

confidence: 99%

Section: Cardiovascular Care In Rheumatologymentioning

confidence: 99%

Cardiorheumatology: cardiac involvement in systemic rheumatic disease

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Rheumatologic disease severity and duration does not always correlate with the presence or degree of atherosclerosis. There is recent evidence that Disease Modifying Anti-Rheumatic Drugs (DMARDs) especially methotrexate may reduce atherosclerosis progression in rheumatoid arthritis [82][83][84][85]. The effect of DMARDs on atherosclerosis in other rheumatologic disorders, such as SLE, is unknown.…”

Section: Resultsmentioning

confidence: 99%

Atherosclerosis and Other Cardiovascular Manifestations of Rheumatologic Diseases

Palaskas¹

2013

Rheumatology (Sunnyvale)

View full text Add to dashboard Cite

Prevalance and importance of cardiovascular diseaes have continued to increase as therapeutic advances has led to increasing life expectancy, and better understanding of the role of the immune system in initiation and progression of inflamation and atherosclerosis. Thus, the need for better understanding of the relationship of rheumatologic diseases and cardiovascular disoders is paramount to permit more effective preventive and therapeutic approches. In our review, we tried whenever applicable, to categorize cardiovascular invovlement as atherosclerosis, myocardial, valvular, and pericardial.

show abstract

“…Полученные данные согласу-ются с результатами A. Guin и соавт. [30], показавших до-стоверное снижение ТКИМ сонных артерий у больных ранним РА при снижении активности заболевания на фо-не монотерапии МТ либо сочетания МТ с сульфасалази-ном и гидроксихлорохином в течение 1 года наблюдения. Интересными представляются данные первого проспек-тивного исследования влияния низкой активности РА на риск ССО [31].…”

Section: Discussionunclassified